Literature DB >> 9669698

Microvascular and cellular responses in the optic nerve of rats with acute experimental allergic encephalomyelitis (EAE).

P Hu1, J Pollard, N Hunt, J Taylor, T Chan-Ling.   

Abstract

The optic nerve of rats with EAE was examined at various times to determine the integrity of the blood-brain barrier (BBB) and to assess monocyte-macrophage, T cell, and microglial responses. In naive control animals, leakage of horseradish peroxidase (HRP) and the presence of cells expressing major histocompatibility complex (MHC) class II antigen were evident in the meninges of the retrobulbar optic nerve. In rats with EAE, microglia in the region of the lamina cribrosa and in the regions adjacent to the meninges became activated from day 7 to 8 postinduction (pi). HRP leakage was also evident in the region of the lamina cribrosa from day 7 to 8 pi. On day 8 pi, infiltration of inflammatory cells and Monastral blue leakage were apparent in the myelinated region of the optic nerve. The intensity of these cellular and vascular changes peaked at day 12 pi, when signs of clinical disease became manifest. Monocytes-macrophages expressing MHC class II and the ED1 antigen, together with lymphocytes expressing the alphabetaT cell receptor, constituted the major proportion of cells associated with inflammatory lesions. Thus: (i) the inherent weakness of the BBB as well as the presence of both antigen (myelin) and MHC class II+ cells in the retrobulbar optic nerve are likely susceptibility factors for the frequent involvement of this region in EAE and multiple sclerosis; and (ii) activation of microglia occurs early in the pathogenesis of experimental optic neuritis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9669698     DOI: 10.1111/j.1750-3639.1998.tb00169.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  7 in total

1.  Breakdown of the blood-retinal barrier induced by activated T cells of nonneural specificity.

Authors:  P Hu; J D Pollard; T Chan-Ling
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

2.  Complex I subunit gene therapy with NDUFA6 ameliorates neurodegeneration in EAE.

Authors:  Venu Talla; Rajeshwari Koilkonda; Vittorio Porciatti; Vince Chiodo; Sanford L Boye; William W Hauswirth; John Guy
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-01-22       Impact factor: 4.799

3.  Gene therapy with mitochondrial heat shock protein 70 suppresses visual loss and optic atrophy in experimental autoimmune encephalomyelitis.

Authors:  Venu Talla; Vittorio Porciatti; Vince Chiodo; Sanford L Boye; William W Hauswirth; John Guy
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-07-11       Impact factor: 4.799

4.  Dual gene therapy with extracellular superoxide dismutase and catalase attenuates experimental optic neuritis.

Authors:  Xiaoping Qi; William W Hauswirth; John Guy
Journal:  Mol Vis       Date:  2007-01-05       Impact factor: 2.367

5.  Damage to the optic chiasm in myelin oligodendrocyte glycoprotein-experimental autoimmune encephalomyelitis mice.

Authors:  Sheryl L Herrera; Vanessa L Palmer; Heather Whittaker; Blair Cardigan Smith; Annie Kim; Angela E Schellenberg; Jonathan D Thiessen; Richard Buist; Marc R Del Bigio; Melanie Martin
Journal:  Magn Reson Insights       Date:  2014-11-09

6.  Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis.

Authors:  Estelle Bettelli; Maria Pagany; Howard L Weiner; Christopher Linington; Raymond A Sobel; Vijay K Kuchroo
Journal:  J Exp Med       Date:  2003-05-05       Impact factor: 14.307

7.  Alleviation of extensive visual pathway dysfunction by a remyelinating drug in a chronic mouse model of multiple sclerosis.

Authors:  Maria T Sekyi; Kelli Lauderdale; Kelley C Atkinson; Batis Golestany; Hawra Karim; Micah Feri; Joselyn S Soto; Cobi Diaz; Sung Hoon Kim; Marianne Cilluffo; Steven Nusinowitz; John A Katzenellenbogen; Seema K Tiwari-Woodruff
Journal:  Brain Pathol       Date:  2021-01-29       Impact factor: 6.508

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.